NewsFlash
News Flash
“It is better to have tried and failed than to have failed to try, but the result’s the same.” – Mike Dennison
Leben (Life aka misc) The Planet (on, and off)
Protests Erupting Across China
“Protesters clash with police as unrest rocks cities across China,” reads CNN’s headline. The Guardian calls it “the biggest wave of civil disobedience on the mainland since Xi Jinping assumed power a decade ago,” noting one crowd numbered over 1,000 protesters. “Crowdsourced lists on social media claim protests have been Read more…
Leben (Life aka misc) Technology
Universal Flu Vaccine May Be Available Within Two Years, Says Scientist
A universal flu vaccine that protects against all strains of the virus could be available in the next two years, according to a leading scientist. An experimental vaccine based on the same mRNA technology used in the highly successful Covid jabs was found to protect mice and ferrets against severe Read more…
Leben (Life aka misc) Technology
Google: 60% Of The Internet Is Duplicate
Google says “60% of the internet is duplicate.” Gary Illyes from Google posted this slide at the Google Search Central Live in Singapore the other day.
Crypto Leben (Life aka misc)
‘Partner-Swapping, Pills…’ NY Post Investigates Sam Bankman-Fried’s ‘FTX Party House’
Are we missing some clarifying details in the saga of Sam Bankman-Fried? The New York Post seems to think so, writing among other things, that inside a glamorous Bahamas penthouse, 10 roommates became “a group of financial renegades that dropped speed, blithely swapped in and out of relationships with one Read more…
Crypto Leben (Life aka misc)
Harvard Paper To Central Banks: Buy Bitcoin
A new working paper by Matthew Ferranti — a fifth-year PhD candidate in Harvard’s economics department and advisee of Ken Rogoff, a former economist at the IMF and the Federal Reserve Board of Governors who is now a Harvard professor — has caused a minor splash. From a report: In Read more…
Leben (Life aka misc)
FDA Approves Most Expensive Drug Ever, a $3.5 Million-per-Dose Gene Therapy For Hemophilia B
U.S. health regulators this week approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the genetic disorder which primarily affects men. Currently, patients Read more…